Abstract Background: For patients with B-cell acute lymphoblastic leukemia (B-ALL), extramedullary relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely unfavorable prognosis. As a new immunotherapy, chimeric antigen receptor T (CAR-T) cell therapy has shown remarkable effects in refractory or relapsed B-ALL (r/r B-ALL). However, there is still a lack of evidence for its efficacy and safety in patients with extramedullary relapse after allo-HSCT. The aim of this study was to evaluate the safety and efficacy of allogeneic CAR-T in such high-risk populations. Method: We conducted a prospective clinical study, during which 7 patients with B-ALL who experienced extramedullary relapse after allo-HSCT were enrolled between October 2019 and January 2025. These patients all received allogeneic CD19 CAR-T cell therapy. We prospectively evaluated the safety, efficacy, and survival outcomes following CAR-T treatment. This study was registered at www.chictr.org.cn (No. ChiCTR2000036350). Results: This study included 7 patients with extramedullary relapse after allo-HSCT. Median age was 21 years (range: 15 - 46 years), and the median follow-up time was 415 days (range: 130 - 1320 days). The last follow-up was conducted until July 5, 2025. All the patients were classified as high-risk patients before transplantation. Four of them were Philadelphia chromosome/BCR-ABL positive (Ph+). The sites of extramedullary relapse included: 5 cases of central nervous system (among which 2 cases were accompanied by BCR-ABL molecular relapse in the bone marrow), 1 case of testicular relapse, and 1 case of extensive extramedullary relapse. The median interval from transplantation to extramedullary relapse was 628 days (44 - 1225 days). All patients received chemotherapy, radiotherapy or targeted therapy to reduce tumor burden before infusion. The infusion dose of CAR-T cells was 4 - 10 × 10⁶/kg. After infusion, one patient developed grade 3 cytokine release syndrome (CRS) and grade 4 immune effector cell-related neurotoxicity syndrome (ICANS), while the remaining patients did not experience grade 2 or higher CRS or ICANS. No patients developed graft-versus-host disease (GVHD), and all adverse events were resolved. In terms of therapeutic efficacy, one patient was considered unresponsive at the first assessment after infusion (54 days after infusion). The remaining 6 patients all achieved complete remission (CR) efficacy. The median duration of CR was 275 days (range: 120 - 1305 days). During the follow-up period, one patient suffered from central nervous system relapse again at 275 days post-infusion, while the other 5 maintained a continuous CR. The expansion of CAR-T cells in peripheral blood peaked between days 8 to 15 post-infusion, with a median peak of 1.90E+05 copies/μg DNA (range: 1.78E+04 – 3.18E+05 copies/μg DNA), and the longest duration of detectable expansion was 1320 days. Furthermore, CAR-T cells were detected in the cerebrospinal fluid of three patients, indicating their capability for targeted migration and central nervous system infiltration. Conclusion: Overall, allogeneic CAR-T therapy has demonstrated excellent safety and durable anti-leukemia effects in high-risk ALL patients with extramedullary relapse after transplantation.
Chen et al. (Mon,) studied this question.